Vera Therapeutics, Inc. VERA
We take great care to ensure that the data presented and summarized in this overview for Vera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VERA
View all-
Avoro Capital Advisors LLC New York, NY5.7MShares$127 Million2.22% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.75MShares$106 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$74.4 Million0.0% of portfolio
-
Abingworth LLP London, X02.96MShares$66 Million19.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$65.1 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.79MShares$62.3 Million4.94% of portfolio
-
Commodore Capital LP New York, NY2.56MShares$57.1 Million6.03% of portfolio
-
Vestal Point Capital, LP New York, NY2.5MShares$55.7 Million4.29% of portfolio
-
Kynam Capital Management, LP Princeton, NJ2.4MShares$53.5 Million4.86% of portfolio
-
Holocene Advisors, LP New York, NY2.2MShares$49 Million0.17% of portfolio
Latest Institutional Activity in VERA
Top Purchases
Top Sells
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Insider Transactions at VERA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2025
|
Patrick G Enright |
BUY
Open market or private purchase
|
Indirect |
40,607
+0.75%
|
$893,354
$22.35 P/Share
|
|
Jun 23
2025
|
Patrick G Enright |
BUY
Open market or private purchase
|
Indirect |
209,393
+3.76%
|
$4,187,860
$20.87 P/Share
|
|
Feb 26
2025
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
9,075
-2.13%
|
$245,025
$27.93 P/Share
|
|
Feb 21
2025
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,613
-4.73%
|
$286,551
$27.89 P/Share
|
|
Feb 18
2025
|
Robert Brenner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,900
+49.47%
|
-
|
|
Feb 18
2025
|
William D. Turner Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+50.0%
|
-
|
|
Feb 18
2025
|
Joseph R Young SVP, FINANCE, CHIEF ACCT OFFCR |
BUY
Grant, award, or other acquisition
|
Direct |
10,740
+14.78%
|
-
|
|
Feb 18
2025
|
David Lee Johnson Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,900
+50.0%
|
-
|
|
Feb 18
2025
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,750
+26.47%
|
-
|
|
Feb 18
2025
|
Sean Grant CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
26,900
+22.39%
|
-
|
|
Jan 08
2025
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
17,500
-3.86%
|
$717,500
$41.85 P/Share
|
|
Jan 08
2025
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+3.67%
|
$35,000
$2.9 P/Share
|
|
Dec 19
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
57,661
+28.65%
|
$115,322
$2.9 P/Share
|
|
Dec 18
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
17,500
-3.89%
|
$752,500
$43.01 P/Share
|
|
Dec 18
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+3.73%
|
$35,000
$2.9 P/Share
|
|
Dec 11
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
17,500
-4.44%
|
$822,500
$47.26 P/Share
|
|
Dec 11
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+3.95%
|
$35,000
$2.9 P/Share
|
|
Nov 25
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
19,375
-4.23%
|
$930,000
$48.36 P/Share
|
|
Nov 25
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,375
+3.99%
|
$38,750
$2.9 P/Share
|
|
Nov 18
2024
|
Jason S Carter Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 248K shares |
|---|---|
| Open market or private purchase | 250K shares |
| Exercise of conversion of derivative security | 265K shares |
| Open market or private sale | 288K shares |
|---|